15/04/25

With the EU HTA Regulation now in force (January 2025), the webinar will explore the critical need to account for vaccines’ specificities in the implementation of the EU HTA Regulation to optimise their access and impact on public health, economy and society across Europe and globally.

The role of immunisation extends beyond mere prevention, becoming a critical pillar for global health security and economic stability. Upcoming vaccine innovation can address major health challenges, but its full benefits depend on broad access, guided thorough vaccine assessments and ultimate inclusion in the National Immunisation Programmes.

This session will also present the key findings from the peer-reviewed publication “Guiding Principles for Evaluating Vaccines in Joint Health Technology Assessment in the EU”, co-authored with leading European vaccine experts.

During this webinar, we will explore the state of play of the EU HTA Regulation focusing on:

What are the unique aspects of vaccines that require specific attention in joint clinical
assessments;
Why vaccine innovation is so vital and why the applicability of the EU HTA Regulation
to vaccines cannot wait any further;
How can the EU HTA Regulation’s processes and methodologies be adapted to account for vaccines’ specificities?

door Idalia Dlugosz